Linus Biotechnology

LinusBio is a New York-based platform diagnostics company founded in 2019, focused on the novel field of temporal exposomics. Its core technology analyzes hair to reveal longitudinal molecular data, functioning as a biological recorder of environmental exposures and physiological changes. The company has achieved significant validation with FDA Breakthrough Device designation for its lead autism diagnostic biomarker and has launched its first commercial test, ClearStrand-ASD. LinusBio is leveraging its platform to build a pipeline targeting other complex CNS and systemic disorders.

Proprietary temporal exposomic sequencing platform that analyzes hair strands using robotics, lasers, and mass spectrometry to release and measure time-stamped molecular features, integrated with an AI pipeline to identify disease-specific biomarker signatures.

LinusBio is a first-mover in commercializing temporal exposomic biomarkers from hair, creating a novel niche. Potential competitors include other companies exploring the exposome via different bio-samples (e.g., blood, urine) or multi-omics platforms, as well as traditional genetic and diagnostic firms expanding into environmental interactions.